Tradestie Institutional Equity Comparison Engine

LCTX vs AGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AGEN Overall Edge

AGEN Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agenus Inc. (AGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus AGEN at 3.7x Forward P/E and 38.9% operating margin (+4.1% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against AGEN sits in BREAKDOWN (31st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AGEN
LCTX 30.7x vs AGEN 3.7x Fwd P/E
Growth & Margin Winner AGEN
Op Margin -280.3% vs 38.9% ยท YoY -61.0% vs +4.1%
Momentum & Technical Winner AGEN
1Y -53.7% vs +45.1% ยท 52W Pos 4% vs 45%
Options & Structure Winner AGEN
BREAKDOWN (100th %ile IV) vs BREAKDOWN (31st %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
AGEN NASDAQ
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.14
-4.06% 1D
Market Cap $289.6M
1M Return -4.06%
1Y Return +45.15%
Forward P/E 3.7x
Unified AI Score
54.2 / 100 HOLD
Tech 48.0 Fund 49.0 Flow 70.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% AGEN +45.15% Spread: +98.82 pp (AGEN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue AGEN Revenue LCTX Op. Margin AGEN Op. Margin Margin Edge
FY2018 $0M $40M -837.9% -336.6% AGEN
FY2019 $0M $150M -1106.0% -46.7% AGEN
FY2020 $0M $90M -1448.4% -133.0% AGEN
FY2021 $0M $300M -1133.6% 8.7% AGEN
FY2022 $10M $100M -153.2% -183.0% LCTX
FY2023 $10M $160M -276.5% -102.1% AGEN
FY2024 $10M $100M -226.1% -116.4% AGEN
FY2025 $10M $110M -251.6% -17.7% AGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (2) vs AGEN (8)
Institutional Metric LCTX AGEN Criterion Row Winner
Market Capitalization Scale $212.1M $289.6M Larger Scale AGEN
Trailing P/E Ratio Valuation 30.7x 27.8x Lower Multiple AGEN
Forward P/E Ratio Valuation 30.7x 3.7x Lower Multiple AGEN
Revenue Growth (YoY) Growth -61.0% +4.1% Higher Growth AGEN
Operating Margin (TTM) Profitability -280.3% 38.9% Higher Margin AGEN
Net Profit Margin Profitability 16.2% 30.8% Higher Margin AGEN
Return on Equity (ROE) Capital Efficiency 4.3% -1278.8% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 45% ($3โ€“$10) Stronger Trend AGEN
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 1.58ฮฒ ยท 77% Vol Lower Realized Risk AGEN
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 54.2 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs AGEN Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AGEN BREAKDOWN
36d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 31st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor AGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.